Brett joined SV as a Venture Partner in 2023.
Brett has more than 10 years’ experience as Chief Medical Officer in both privately and publicly listed companies in the US and UK, including Circassia (Oxford, 2012-2013), Theravance Biopharma (California, 2013-2022) and ReViral (Stevenage, 2022-2023 including a transition period in Pfizer after ReViral was acquired).
Prior to this Brett spent 15 years at GlaxoSmithKline in a variety of executive roles in South Africa (1997-1999) and the UK (1999-2012), spanning early drug discovery to clinical development and commercialization, including anti-infectives, immunology and respiratory products. Brett was selected as one of the first Vice President Medicines Development Leaders at GSK and led the development of inhaled products for the treatment of asthma and COPD, including Relvar® / Breo® and Arnuity®.
Brett has served as a non-executive director on several Boards, including Autifony (UK, 2011-2012), Reacta (UK, 2014-2016), Aimmune (US, 2018-2020 until the company’s acquisition by Nestle) and Aravax (Australia, 2022-present).
Brett received his medical degree (MBBCh) from the University of Witwatersrand, South Africa and his Masters in Business Administration (MBA) with distinction from the Open University, UK.